198 related articles for article (PubMed ID: 33560188)
1. Evaluation of Breast Edema Findings at T2-weighted Breast MRI Is Useful for Diagnosing Occult Inflammatory Breast Cancer and Can Predict Prognosis after Neoadjuvant Chemotherapy.
Harada TL; Uematsu T; Nakashima K; Kawabata T; Nishimura S; Takahashi K; Tadokoro Y; Hayashi T; Tsuchiya K; Watanabe J; Sugino T
Radiology; 2021 Apr; 299(1):53-62. PubMed ID: 33560188
[TBL] [Abstract][Full Text] [Related]
2. Microcalcifications and Peritumoral Edema Predict Survival Outcome in Luminal Breast Cancer Treated with Neoadjuvant Chemotherapy.
Kwon BR; Shin SU; Kim SY; Choi Y; Cho N; Kim SM; Yi A; Yun B; Jang M; Ha SM; Lee SH; Chang JM; Moon WK
Radiology; 2022 Aug; 304(2):310-319. PubMed ID: 35536129
[TBL] [Abstract][Full Text] [Related]
3. Can T2-weighted 3-T breast MRI predict clinically occult inflammatory breast cancer before pathological examination? A single-center experience.
Uematsu T; Kasami M; Watanabe J
Breast Cancer; 2014 Jan; 21(1):115-21. PubMed ID: 23104394
[TBL] [Abstract][Full Text] [Related]
4. Is evaluation of the presence of prepectoral edema on T2-weighted with fat-suppression 3 T breast MRI a simple and readily available noninvasive technique for estimation of prognosis in patients with breast cancer?
Uematsu T; Kasami M; Watanabe J
Breast Cancer; 2014 Nov; 21(6):684-92. PubMed ID: 23341125
[TBL] [Abstract][Full Text] [Related]
5. Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?
Harada TL; Uematsu T; Nakashima K; Sugino T; Nishimura S; Takahashi K; Hayashi T; Tadokoro Y; Watanabe J; Nakamoto S; Ito T
Eur Radiol; 2020 Jun; 30(6):3363-3370. PubMed ID: 32062698
[TBL] [Abstract][Full Text] [Related]
6. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
[TBL] [Abstract][Full Text] [Related]
7. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer.
Eun NL; Kang D; Son EJ; Park JS; Youk JH; Kim JA; Gweon HM
Radiology; 2020 Jan; 294(1):31-41. PubMed ID: 31769740
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival.
Bae MS; Shin SU; Ryu HS; Han W; Im SA; Park IA; Noh DY; Moon WK
Radiology; 2016 Nov; 281(2):392-400. PubMed ID: 27195438
[TBL] [Abstract][Full Text] [Related]
9. Classification of breast edema on T2-weighted imaging for predicting sentinel lymph node metastasis and biological behavior in breast cancer.
Xie S; Tang W; Zhang C; Wang J; Wang M; Zhou Y
Clin Radiol; 2024 Apr; ():. PubMed ID: 38763808
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade.
Jacene HA; Youn T; DiPiro PJ; Hu J; Cheng SC; Franchetti Y; Shah H; Bellon JR; Warren L; Schlosnagle E; Nakhlis F; Rosenbluth J; Yeh E; Overmoyer B;
Clin Breast Cancer; 2019 Apr; 19(2):146-155. PubMed ID: 30584057
[TBL] [Abstract][Full Text] [Related]
11. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.
Kim R; Chang JM; Lee HB; Lee SH; Kim SY; Kim ES; Cho N; Moon WK
Radiology; 2019 Oct; 293(1):49-57. PubMed ID: 31407967
[TBL] [Abstract][Full Text] [Related]
12. Can peritumoral edema evaluated by Magnetic Resonance Imaging before neoadjuvant chemotherapy predict complete pathological response in breast cancer?
Cakir Pekoz B; Dilek O; Koseci T; Tas ZA; Irkorucu O; Gulek B
Scott Med J; 2023 Aug; 68(3):121-128. PubMed ID: 37161314
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
[TBL] [Abstract][Full Text] [Related]
14. Development of CNS metastases and survival in patients with inflammatory breast cancer.
Uemura MI; French JT; Hess KR; Liu D; Raghav K; Hortobagyi GN; Arun BK; Valero V; Ueno NT; Alvarez RH; Woodward WA; Debeb BG; Moulder SL; Lim B; Tripathy D; Ibrahim NK
Cancer; 2018 Jun; 124(11):2299-2305. PubMed ID: 29579338
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
16. Added Value of MRI for Invasive Breast Cancer including the Entire Axilla for Evaluation of High-Level or Advanced Axillary Lymph Node Metastasis in the Post-ACOSOG Z0011 Trial Era.
Byon JH; Park YV; Yoon JH; Moon HJ; Kim EK; Kim MJ; You JK
Radiology; 2021 Jul; 300(1):46-54. PubMed ID: 33904772
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of MRI Assessment of Residual Peritumoral Edema in Breast Cancer Treated With Neoadjuvant Chemotherapy.
Shigematsu H; Fujimoto M; Kobayashi Y; Yasui D; Komoto D; Matsuura N; Kuraoka K; Yoshiyama T
J Magn Reson Imaging; 2024 May; ():. PubMed ID: 38809133
[TBL] [Abstract][Full Text] [Related]
18. Invasive Breast Cancer: Prognostic Value of Peritumoral Edema Identified at Preoperative MR Imaging.
Cheon H; Kim HJ; Kim TH; Ryeom HK; Lee J; Kim GC; Yuk JS; Kim WH
Radiology; 2018 Apr; 287(1):68-75. PubMed ID: 29315062
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory breast cancer appearance at presentation is associated with overall survival.
Balema W; Liu D; Shen Y; El-Zein R; Debeb BG; Kai M; Overmoyer B; Miller KD; Le-Petross HT; Ueno NT; Woodward WA
Cancer Med; 2021 Sep; 10(18):6261-6272. PubMed ID: 34327874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
